Startup Raises $23m for Flesh-eating Bacteria Drug

The proceeds will be used for a late-stage clinical study for treating what is commonly known as 'flesh-eating bacteria' and other severe infections.

comments Print
Atox Bio, a biotech startup that traces its origins to Hebrew University, said yesterday it has raised $23 million from an investment group led by SR One, the venture capital arm of the British drug company...